Novartis AG (NYSE:NVS) major shareholder Bioventures Ltd Novartis sold 43,800 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $1.92, for a total value of $84,096.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Bioventures Ltd Novartis also recently made the following trade(s):

  • On Wednesday, March 13th, Bioventures Ltd Novartis sold 132,738 shares of Novartis stock. The shares were sold at an average price of $2.12, for a total value of $281,404.56.

Shares of NYSE:NVS opened at $93.29 on Friday. The firm has a market cap of $212.57 billion, a price-to-earnings ratio of 18.33, a P/E/G ratio of 1.96 and a beta of 0.67. Novartis AG has a 12-month low of $72.30 and a 12-month high of $93.62. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.20 and a quick ratio of 0.97.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Wednesday, January 30th. The company reported $1.24 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.33 by ($0.09). The company had revenue of $13.27 billion for the quarter, compared to analysts’ expectations of $13.33 billion. Novartis had a net margin of 24.30% and a return on equity of 15.66%. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.21 EPS. As a group, research analysts anticipate that Novartis AG will post 5.42 EPS for the current year.

The business also recently disclosed an annual dividend, which was paid on Wednesday, March 13th. Shareholders of record on Tuesday, March 5th were paid a dividend of $2.8646 per share. This is a boost from Novartis’s previous annual dividend of $2.33. The ex-dividend date was Monday, March 4th. This represents a yield of 3.27%. Novartis’s payout ratio is presently 36.15%.

Several institutional investors have recently bought and sold shares of NVS. BlackRock Inc. increased its holdings in shares of Novartis by 223.5% in the 4th quarter. BlackRock Inc. now owns 11,439,298 shares of the company’s stock worth $981,607,000 after purchasing an additional 7,902,964 shares in the last quarter. FMR LLC increased its holdings in shares of Novartis by 441.6% in the 4th quarter. FMR LLC now owns 7,016,047 shares of the company’s stock worth $602,046,000 after purchasing an additional 5,720,650 shares in the last quarter. Matthew Goff Investment Advisor LLC increased its holdings in shares of Novartis by 7,454.1% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 2,945,178 shares of the company’s stock worth $38,988,000 after purchasing an additional 2,906,190 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Novartis by 25.1% in the fourth quarter. Bank of America Corp DE now owns 9,053,828 shares of the company’s stock worth $776,909,000 after acquiring an additional 1,817,005 shares during the period. Finally, Mawer Investment Management Ltd. grew its holdings in shares of Novartis by 53.4% in the fourth quarter. Mawer Investment Management Ltd. now owns 4,764,486 shares of the company’s stock worth $408,841,000 after acquiring an additional 1,658,037 shares during the period. 11.68% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. cut Novartis from a “neutral” rating to an “underweight” rating in a research note on Wednesday, January 2nd. Jefferies Financial Group reiterated a “buy” rating and set a $105.00 price objective on shares of Novartis in a research note on Tuesday, December 11th. Cowen upgraded Novartis from a “market perform” rating to an “outperform” rating and set a $100.00 price objective for the company in a research note on Monday, November 26th. Credit Suisse Group cut Novartis to a “sell” rating in a research note on Thursday, December 20th. Finally, Barclays cut Novartis from an “equal weight” rating to a “sell” rating in a research note on Friday, December 7th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $90.94.

ILLEGAL ACTIVITY NOTICE: “Bioventures Ltd Novartis Sells 43,800 Shares of Novartis AG (NVS) Stock” was first posted by Marea Informative and is the sole property of of Marea Informative. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.mareainformativa.com/news/2019/03/17/bioventures-ltd-novartis-sells-43800-shares-of-novartis-ag-nvs-stock.html.

About Novartis

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Featured Article: How are institutional investors different from individual investors?

Insider Buying and Selling by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.